Rein Therapeutics Inc. (RNTX)
RNTX Stock Price Chart
Explore Rein Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze RNTX price movements and trends.
RNTX Company Profile
Discover essential business fundamentals and corporate details for Rein Therapeutics Inc. (RNTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jun 2017
Employees
11.00
Website
http://www.reintx.comCEO
James Brian Windsor
Description
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
RNTX Financial Timeline
Browse a chronological timeline of Rein Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.25.
Earnings released on 14 Aug 2025
EPS came in at -$0.28 falling short of the estimated -$0.22 by -27.27%.
Earnings released on 7 Apr 2025
EPS came in at -$0.26 falling short of the estimated -$0.14 by -85.71%.
Earnings released on 31 Dec 2024
EPS came in at -$1.89 falling short of the estimated -$0.46 by -310.68%.
Earnings released on 14 Nov 2024
EPS came in at -$0.27 falling short of the estimated -$0.25 by -8.00%.
Earnings released on 14 Aug 2024
EPS came in at -$0.45 falling short of the estimated -$0.25 by -80.00%.
Earnings released on 31 Mar 2024
EPS came in at -$0.86 falling short of the estimated -$0.14 by -512.00%.
Earnings released on 31 Dec 2023
EPS came in at -$1.54 falling short of the estimated -$0.16 by -840.03%.
Earnings released on 30 Sept 2023
EPS came in at -$0.40 falling short of the estimated -$0.20 by -101.16%.
Earnings released on 30 Jun 2023
EPS came in at -$0.39 surpassing the estimated -$0.40 by +1.62%.
Earnings released on 8 May 2023
Earnings released on 20 Mar 2023
Stock split effective on 11 Nov 2022
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
RNTX Stock Performance
Access detailed RNTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.